Raymond James raises Everest Group stock price target on capital returns

Raymond James raised Everest Group’s price target to $400 from $350 and kept an Outperform rating, citing a 2026 transition year as the insurer exits commercial retail insurance and potentially unlocks capital for shareholder returns. Q1 2026 EPS beat estimates at $16.08 versus $14.20, though revenue missed at $4.07 billion versus $4.26 billion and gross written premiums fell about 19% year over year on a comparable basis. The company repurchased $331 million of stock in Q1 and $100 million in April, with management lifting the quarterly buyback floor to $300 million for 2026.

Analysis

EG is increasingly a capital-return story disguised as a turnaround. The market is still anchoring on top-line compression, but the important second-order effect is that a smaller, cleaner book should produce less earnings volatility and higher excess capital generation, which matters more for valuation in a sub-1.0x book multiple name than premium growth does. If underwriting stays near current profitability, buybacks can become the dominant EPS driver for multiple years, creating a self-reinforcing rerating loop as per-share book value compounds faster than reported premium volume declines.

The main winner is the equity itself: management is effectively signaling that internal deployment opportunities are limited, so the hurdle rate on repurchases is now the cleanest use of capital. That tends to compress the discount to book for insurers because investors start valuing normalized distributable capital rather than headline premiums. The bigger hidden beneficiary may be other P&C insurers with credible capital return programs, since EG’s move reinforces the idea that shrinking the book can be value-accretive when underwriting discipline improves.

The risk is that this is a classic “good execution, bad optics” setup: if revenue and premium declines persist for several quarters, momentum investors may keep exiting even as intrinsic value rises. The catalyst window is months, not days—next quarterly reporting should matter more than macro noise, because the market needs evidence that the cleaner mix is translating into stable combined ratios and sustained buyback capacity. A sharp deterioration in catastrophe losses or reserve development would be the key reversal trigger, because the valuation case depends on the market trusting the quality of current earnings.

Consensus may still be underestimating how much repurchases can matter at 0.9x book. At that starting point, a sustained 6-8% annual reduction in share count can lift EPS and book value per share enough to justify a faster multiple normalization than the street is modeling, especially if the exit from low-quality lines reduces capital intensity. The market is likely too focused on the absence of growth and not enough on the fact that in insurance, disciplined contraction can be more valuable than noisy expansion.

Key Decisions for Investors

• Long EG common for a 6-12 month re-rating trade; target a move toward 1.0-1.1x book as buybacks compound per-share value, with downside mainly tied to underwriting slippage or reserve surprises.
• Use a call spread in EG rather than outright stock if you want defined risk into the next 1-2 earnings prints; the setup favors a gradual rerating, not a single catalyst gap.
• Pair trade: long EG / short a higher-multiple P&C insurer with weaker capital return discipline over the next 1-2 quarters; the relative trade should benefit if investors reward buyback-heavy balance sheets.
• Add on weakness after any post-earnings selloff that is driven by premium declines rather than loss-ratio deterioration; that would likely be the best entry because the market is still over-penalizing revenue contraction.
• Take partial profits if EG approaches or exceeds 1.1x book before the market has visibility on 2026 underwriting normalization; at that point the valuation case becomes less asymmetric.